Tricida (TCDA) Tops Q3 EPS by 13c

Tricida (NASDAQ: TCDA) reported Q3 EPS of ($0.71), $0.13 better than the analyst estimate of ($0.84).

“We’ve made significant progress on our major initiatives supporting both our plan to submit our New Drug Application (NDA) under the Accelerated Approval Pathway in the second half of 2019 and our pre-launch activities for TRC101,” said Gerrit Klaerner, Ph.D., Tricida’s chief executive officer and president. “Our pre-launch activities, initiated at the American Society of Nephrology (ASN) Kidney Week 2018 meeting, included a unique, non-branded metabolic acidosis disease awareness campaign. Nephrologists were eager to hear the latest information about metabolic acidosis and its potential impact on CKD progression. We also drew significant attention at the meeting with our new mobile app, branded as Neph+, featuring the 8-variable kidney failure risk equation, KDIGO guideline recommendations and a convenient calculator for equations commonly used by nephrologists.”

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
• NOV Inc (NOV) Tops Q1 EPS by 3c; offers guidance